These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2102790)

  • 1. Clotting factors in tumour tissue: implications for cancer therapy.
    Zacharski LR; Memoli VA; Costantini V; Wojtukiewicz MZ; Ornstein DL
    Blood Coagul Fibrinolysis; 1990; 1(1):71-8. PubMed ID: 2102790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathways of coagulation/fibrinolysis activation in malignancy.
    Zacharski LR; Wojtukiewicz MZ; Costantini V; Ornstein DL; Memoli VA
    Semin Thromb Hemost; 1992 Jan; 18(1):104-16. PubMed ID: 1574711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
    Zacharski LR; Memoli VA; Ornstein DL; Rousseau SM; Kisiel W; Kudryk BJ
    J Natl Cancer Inst; 1993 Aug; 85(15):1225-30. PubMed ID: 8331683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology.
    Winter PC
    Hematol Oncol; 2006 Sep; 24(3):126-33. PubMed ID: 16783843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procoagulant mechanisms in tumour cells.
    Falanga A; Panova-Noeva M; Russo L
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):49-60. PubMed ID: 19285272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
    Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
    Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of blood coagulation in cancer: implications for tumour progression.
    Lima LG; Monteiro RQ
    Biosci Rep; 2013 Sep; 33(5):. PubMed ID: 23889169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The coagulation system as a target for experimental therapy of human gliomas.
    Loynes JT; Zacharski LR
    Expert Opin Ther Targets; 2003 Jun; 7(3):399-404. PubMed ID: 12783575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
    Korte W
    Clin Chem Lab Med; 2000 Aug; 38(8):679-92. PubMed ID: 11071061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.
    Weitz JI; Leslie B
    J Clin Invest; 1990 Jul; 86(1):203-12. PubMed ID: 2365816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer.
    Reijerkerk A; Voest EE; Gebbink MF
    Eur J Cancer; 2000 Aug; 36(13 Spec No):1695-705. PubMed ID: 10959055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays.
    Choi Q; Kim JE; Hyun J; Han KS; Kim HK
    Thromb Res; 2013 Jul; 132(1):e70-5. PubMed ID: 23769659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
    Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
    Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
    Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
    Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procoagulants and anticoagulants in fetal blood. A literature survey.
    Uszyński M; Uszyński W; Szymański M
    Folia Histochem Cytobiol; 2009; 47(4):545-50. PubMed ID: 20430718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase plasminogen activator system as a potential target for cancer therapy.
    Mekkawy AH; Morris DL; Pourgholami MH
    Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin in tumor progression and metastatic dissemination.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2007 Oct; 33(7):688-94. PubMed ID: 18000796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer and blood coagulation: molecular aspects.
    Bromberg ME; Cappello M
    Cancer J Sci Am; 1999; 5(3):132-8. PubMed ID: 10367166
    [No Abstract]   [Full Text] [Related]  

  • 20. Polyphosphate modulates blood coagulation and fibrinolysis.
    Smith SA; Mutch NJ; Baskar D; Rohloff P; Docampo R; Morrissey JH
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):903-8. PubMed ID: 16410357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.